Chong Kun Dang, KR7185750007

Chong Kun Dang stock: company reports 7.5% sales growth

Published on 11/17/2026 at 03:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Chong Kun Dang stock remains in focus after nine-month sales exceeded KRW 1.36 trillion. Third-quarter operating profit improved as research spending stayed high.

Nine-month growth and R&D spending

  • Chong Kun Dang increased nine-month revenue while net income edged higher.
  • Third-quarter operating profit improved as the operating margin widened.
  • The company is expanding specialized R&D subsidiaries alongside clinical investment.
Chong Kun Dang, KR7185750007, Illustration mit AI erstellt.

Chong Kun Dang reported nine-month revenue growth of 7.5% for 2026, while its third-quarter operating profit improved, according to DailyPharm. The report was based on the quarterly filing submitted on November 16.

Revenue growth meets heavier investment

Consolidated revenue for the first nine months reached KRW 1.3605 trillion, compared with KRW 1.2656 trillion a year earlier. Operating profit was KRW 54.7 billion, down from KRW 57.1 billion, while net income rose to KRW 52.4 billion from KRW 51.6 billion.

Third-quarter revenue increased 1.0% to KRW 434.3 billion. Operating profit gained 5.1% to KRW 22.0 billion, lifting the operating margin to 5.1% from 4.9% a year earlier.

Wegovy supports the product portfolio

Wegovy contributed to sales growth through Chong Kun Dang's domestic co-promotion agreement with Novo Nordisk Korea. Other named products included Prolia for osteoporosis, Atozet for lipid treatment, Godex for liver disease and Fexuclue for gastroesophageal reflux disease.

Research and development spending reached KRW 161.0 billion in the first nine months, equal to 11.84% of revenue. Clinical-trial spending had already exceeded the previous full-year amount, while the company continued to build specialized subsidiaries for drug development, research and production.

Business model and market position

Chong Kun Dang is a South Korean pharmaceutical company that develops and sells prescription medicines across areas including obesity, osteoporosis, lipid disorders and gastroesophageal reflux disease. It operates as the pharmaceutical business within the Chong Kun Dang group, whose portfolio also covers chemical ingredients, biotechnology and health foods. The company serves the domestic market while building longer-term capabilities in novel-drug development and biologic therapies.

Chong Kun Dang at a glance

  • Company: Chong Kun Dang
  • ISIN: KR7185750007
  • Reporting period: First nine months and third quarter of 2026
  • Nine-month revenue: KRW 1.3605 trillion
  • Nine-month operating profit: KRW 54.7 billion
  • Nine-month net income: KRW 52.4 billion
  • Nine-month R&D spending: KRW 161.0 billion

South Korean equities trade against the broader KOSPI market backdrop.

More news and analyses on Chong Kun Dang stock are available here.

Disclaimer...
en | KR7185750007 | CHONG KUN DANG | boerse | 70523984 | bgmi